Capebio™ was licensed to manufacture rapid COVID-19 polymerase chain reaction test kits. The test kit was co-developed by Capebio™ and the CSIR. The work undertaken by the CSIR, involved biomanufacturing and purification of the enzymes used in the kit as well as testing robustness and scalability which were demonstrated internally by the CSIR and validated externally by the NHLS. Capebio™ has already commenced industrial-scale manufacturing of the test kits at its Centurion facilities. At full operational capacity, the company will be able to produce up to 5 000 kits a day.